- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 29, 2024Robins Kaplan Mourns Death of New York Associate Waleed Abbasi
-
April 29, 2024Robins Kaplan Secures $7.75 Million Verdict in Aerosol Dust Remover Abuse Case
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
May 20, 2024The Present and Future of DEI
-
May 23, 202414th Annual Disability Justice Seminar
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
April 30, 2024A World Without Non-Competes: Protecting Confidential Information and Trade Secrets Following the FTC's Ban
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Bristol-Myers Squibb Co. v. Nanocopoeia, LLC
Sprycel® (dasatinib)
April 10, 2023
Case Name: Bristol-Myers Squibb Co. v. Nanocopoeia, LLC, No. 22-cv-1283, 2023 WL 2867945 (D. Minn. Apr. 10, 2023) (Menendez, J.)
Drug Product and Patent(s)-in-Suit: Sprycel® (dasatinib); U.S. Patents Nos. 7,491,725 (“the ’725 patent”) and 8,680,103 (“the ’103 patent”)
Nature of the Case and Issue(s) Presented: BMS’s Sprycel is indicated to treat certain types of leukemia and contains dasatinib in the crystalline monohydrate form. The patents-in-suit claim the crystalline form of dasatinib. Nanocopoeia filed a motion for judgment on the pleadings, arguing that it did not infringe the patents-in-suit, which the court denied.
Why BMS Prevailed: BMS raised several procedural challenges, arguing: (i) it can survive a motion for judgement on the pleadings in the Hatch-Waxman context simply by pleading the elements of artificial infringement; and (ii) the court cannot consider documents attached to, and necessarily embraced by, the pleadings, such as Nanocopoeia’s NDA. The court rejected both arguments.
The court explained that there are two types of hypothetical infringement cases under Hatch-Waxman: those in which the specifications in the defendant’s NDA directly answer the question of infringement and those in which the NDA specifications are ambiguous and do not directly answer the infringement inquiry. In a highly redacted opinion, the court found that Nanocopoeia’s NDA did not directly address infringement and found that there were disputes of material fact that precluded judgment on the pleadings.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.